Patents by Inventor Jill Detmer

Jill Detmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10968487
    Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: April 6, 2021
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
  • Publication number: 20180223377
    Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
    Type: Application
    Filed: April 4, 2018
    Publication date: August 9, 2018
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
  • Patent number: 9938584
    Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: April 10, 2018
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
  • Publication number: 20170137894
    Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
    Type: Application
    Filed: January 31, 2017
    Publication date: May 18, 2017
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
  • Patent number: 9605321
    Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: March 28, 2017
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
  • Publication number: 20150094231
    Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
    Type: Application
    Filed: December 12, 2014
    Publication date: April 2, 2015
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.
    Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
  • Patent number: 8940486
    Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
    Type: Grant
    Filed: January 4, 2011
    Date of Patent: January 27, 2015
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Jill Detmer, Arejas Uzgiris, Andy Ying
  • Publication number: 20120288863
    Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
    Type: Application
    Filed: January 4, 2011
    Publication date: November 15, 2012
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.
    Inventors: Jill Detmer, Arejas Uzgiris, Andy Ying
  • Patent number: 7993838
    Abstract: Provided are nucleic acid sequences that are used to prepare primers and probes that are used in a kinetic polymerase chain reaction (kPCR) assay to detect influenza viruses in a human or animal subject. The starting material for the kPCR assays may be DNA or RNA and the assays may be conducted in a singleplex assay to detect a single influenza virus or in a multiplex assay to detect multiple influenza viruses. The primers and probes have utility in the detection and quantification of type A and type B influenza viruses (INFA and INFB, respectively) and have been shown to be effective for the detection and quantification of all the known INFA subtypes, namely, H1, H2, H3, H4, H5, H6, H7, H8, and H9.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: August 9, 2011
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Jill Detmer, Charlene Bush-Donovan
  • Publication number: 20110003309
    Abstract: Provided are non-competitive internal controls for use in nucleic acid tests (NATs), which are obtained from the organisms Methanobacterium thermoautrophicum (MET) and Zea mays (Corn). The non-competitive internal controls have utility in DNA and RNA NATs selected from Influenza A, Influenza B, parainfluenza viruses 1 to 4 (PIV-1 to PIV-4), respiratory syncytial virus type A (RSV A), RSV B, human metapneumovirus (hMPV), Chlamydia trachomatis (CT), and Neisseria gonorrhea (GC), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human Immunodeficiency Virus I (HIV-1), and Severe Acute Respiratory Syndrome (SARS).
    Type: Application
    Filed: March 19, 2009
    Publication date: January 6, 2011
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.
    Inventors: Jill Detmer, Xiaoqiao Jiang, Minh Le, David Sherman
  • Publication number: 20100330548
    Abstract: Provided are nucleic acid sequences that are used to prepare primers and probes that are used in a kinetic polymerase chain reaction (kPCR) assay to detect influenza viruses in a human or animal subject. The starting material for the kPCR assays may be DNA or RNA and the assays may be conducted in a singleplex assay to detect a single influenza virus or in a multiplex assay to detect multiple influenza viruses. The primers and probes have utility in the detection and quantification of type A and type B influenza viruses (INFA and INFB, respectively) and have been shown to be effective for the detection and quantification of all the known INFA subtypes, namely, H1, H2, H3, H4, H5, H6, H7, H8, and H9.
    Type: Application
    Filed: April 20, 2007
    Publication date: December 30, 2010
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.
    Inventors: Jill Detmer, Charlene Bush-Donovan
  • Publication number: 20100041019
    Abstract: Provided are nucleic acid primers and probes for use in diagnostic assays to screen for respiratory infections, such as respiratory syncytial virus (“RSV”) and human metapneumovirus (hMPV). The primers and probes may be used to screen for RSV or hMPV in a singleplex assay or they may be used in a multiplex assay to simultaneously screen for RSV and hMPV, or RSV and/or hMPV and any of the following viruses: influenza A, and influenza B, parainfluenza viruses, adenovirus, coronavirus, and rhinoviruses.
    Type: Application
    Filed: October 2, 2007
    Publication date: February 18, 2010
    Inventors: Jill Detmer, Sukhwinder Sangha, Charlene Bush-Donovan